{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:49:36Z","timestamp":1793886576152,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072856"],"award-info":[{"award-number":["82072856"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403518"],"award-info":[{"award-number":["82403518"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072856"],"award-info":[{"award-number":["82072856"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403518"],"award-info":[{"award-number":["82403518"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Widespread peritoneal metastasis is a key reason for high mortality in ovarian cancer and understanding its mechanisms will offer new targets for the effective treatment of metastatic ovarian cancer. Our previous research revealed that collagen type I alpha 1 (COL1A1)-induced upregulation of lysyl oxidase-like 2 (LOXL2) was markedly overexpressed in ovarian cancer tissue samples and ascites. LOXL2 serves as an independent risk factor for predicting prognosis and its high expression is associated with high-risk clinical factors. LOXL2 promoted migration and invasion of ovarian cancer cells and metastasis of transplanted tumors in the xenograft mouse model. Here we determined that, mechanistically, COL1A1 activated the EGFR\u2013MEK\u2013ERK signaling pathway, which subsequently facilitated the nuclear translocation of SP1. SP1 binds to the promoter region of LOXL2, augmenting its transcription. Meanwhile, LOXL2 interacts with EGFR, protecting it from lysosomal degradation and enhancing protein stability. Finally, EGFR activates the MEK\u2013ERK signaling pathway, promoting the translocation of SP1 and forming positive feedback. Our findings confirmed the molecular mechanism by which COL1A1-induced upregulation of LOXL2 promotes ovarian cancer metastasis through a positive feedback loop involving EGFR\u2013MEK\u2013ERK\u2013SP1, offering novel scientific insights and potential therapeutic targets for inhibiting ovarian cancer metastasis.<\/jats:p>","DOI":"10.1038\/s12276-026-01675-6","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:53:22Z","timestamp":1773201202000},"page":"864-878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["COL1A1-induced LOXL2 promotes ovarian cancer metastasis via a feedback loop upon inhibiting EGFR lysosomal degradation"],"prefix":"10.1038","volume":"58","author":[{"given":"Zhangjin","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingkai","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanliang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunshan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"1675_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"1675_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cort\u00e9s-Guiral","year":"2021","unstructured":"Cort\u00e9s-Guiral, D. et al. Primary and metastatic peritoneal surface malignancies. Nat. Rev. Dis. Primers 7, 91 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1675_CR3","first-page":"609","volume":"80","author":"MA Roett","year":"2009","unstructured":"Roett, M. A. & Evans, P. Ovarian cancer: an overview. Am. Fam. Physician 80, 609\u2013616 (2009).","journal-title":"Am. Fam. Physician"},{"key":"1675_CR4","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J. Clin. 69, 280\u2013304 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"1675_CR5","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux, S., Gourley, C., Vergote, I. & Oza, A. M. Epithelial ovarian cancer. Lancet 393, 1240\u20131253 (2019).","journal-title":"Lancet"},{"key":"1675_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112153","volume":"394","author":"M Li","year":"2020","unstructured":"Li, M. et al. Microenvironment remodeled by tumor and stromal cells elevates fibroblast-derived COL1A1 and facilitates ovarian cancer metastasis. Exp. Cell Res. 394, 112153 (2020).","journal-title":"Exp. Cell Res."},{"key":"1675_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.31236","volume":"72","author":"W Chen","year":"2020","unstructured":"Chen, W. et al. Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis. Hepatology 72, 729\u2013741 (2020).","journal-title":"Hepatology"},{"key":"1675_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01942-y","volume":"21","author":"F Cheng","year":"2023","unstructured":"Cheng, F. et al. Mesenchymal stem cell-derived exosomal miR-27b-3p alleviates liver fibrosis via downregulating YAP\/LOXL2 pathway. J. Nanobiotechnol. 21, 195 (2023).","journal-title":"J. Nanobiotechnol."},{"key":"1675_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41388-019-0969-1","volume":"39","author":"JP Cebri\u00e0-Costa","year":"2020","unstructured":"Cebri\u00e0-Costa, J. P. et al. LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells. Oncogene 39, 79\u2013121 (2020).","journal-title":"Oncogene"},{"key":"1675_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4012590","volume":"2019","author":"P Xie","year":"2019","unstructured":"Xie, P., Yu, H., Wang, F., Yan, F. & He, X. Inhibition of LOXL2 enhances the radiosensitivity of castration-resistant prostate cancer cells associated with the reversal of the EMT process. Biomed. Res. Int. 2019, 4012590 (2019).","journal-title":"Biomed. Res. Int."},{"key":"1675_CR11","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/1878-0261.13529","volume":"17","author":"Q Xia","year":"2023","unstructured":"Xia, Q. et al. A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer. Mol. Oncol. 17, 2451\u20132471 (2023).","journal-title":"Mol. Oncol."},{"key":"1675_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1136\/gutjnl-2021-325564","volume":"72","author":"M Alonso-Nocelo","year":"2023","unstructured":"Alonso-Nocelo, M. et al. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Gut 72, 345\u2013359 (2023).","journal-title":"Gut"},{"key":"1675_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13046-017-0533-1","volume":"36","author":"M Wang","year":"2017","unstructured":"Wang, M. et al. HIF-1\u03b1 promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. J. Exp. Clin. Cancer Res. 36, 60 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1675_CR14","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/onc.2016.358","volume":"36","author":"DH Peng","year":"2017","unstructured":"Peng, D. H. et al. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene 36, 1925\u20131938 (2017).","journal-title":"Oncogene"},{"key":"1675_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13046-023-02929-1","volume":"43","author":"YJ Zhou","year":"2024","unstructured":"Zhou, Y. J. et al. RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1\/FAK\/SRC signaling. J. Exp. Clin. Cancer Res. 43, 45 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1675_CR16","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1074\/jbc.C112.421768","volume":"288","author":"L Xu","year":"2013","unstructured":"Xu, L. et al. Post-translational modifications of recombinant human lysyl oxidase-like 2 (rhLOXL2) secreted from Drosophila S2 cells. J. Biol. Chem. 288, 5357\u20135363 (2013).","journal-title":"J. Biol. Chem."},{"key":"1675_CR17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891\u2013906 (2009).","journal-title":"Cell"},{"key":"1675_CR18","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1242\/jcs.067009","volume":"124","author":"PP Provenzano","year":"2011","unstructured":"Provenzano, P. P. & Keely, P. J. Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and Rho GTPase signaling. J. Cell Sci. 124, 1195\u20131205 (2011).","journal-title":"J. Cell Sci."},{"key":"1675_CR19","doi-asserted-by":"publisher","first-page":"G317","DOI":"10.1152\/ajpgi.00363.2011","volume":"302","author":"S Muthusamy","year":"2012","unstructured":"Muthusamy, S. et al. PKC\u03b4-dependent activation of ERK1\/2 leads to upregulation of the human NHE2 transcriptional activity in intestinal epithelial cell line C2BBe1. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G317\u2013G325 (2012).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1675_CR20","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.3390\/ijms24065164","volume":"24","author":"S Safe","year":"2023","unstructured":"Safe, S. Specificity proteins (Sp) and cancer. Int. J. Mol. Sci. 24, 5164 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1675_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41388-021-02014-x","volume":"41","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. HOTAIR\/Sp1\/miR-199a critically regulates cancer stemness and malignant progression of cutaneous squamous cell carcinoma. Oncogene 41, 99\u2013111 (2022).","journal-title":"Oncogene"},{"key":"1675_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13046-022-02336-y","volume":"41","author":"D Wu","year":"2022","unstructured":"Wu, D. et al. HIF1\u03b1\u2013SP1 interaction disrupts the circ-0001875\/miR-31-5p\/SP1 regulatory loop under a hypoxic microenvironment and promotes non-small cell lung cancer progression. J. Exp. Clin. Cancer Res. 41, 156 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1675_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41392-022-01096-7","volume":"7","author":"G Zhao","year":"2022","unstructured":"Zhao, G. et al. DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2. Signal Transduct. Target. Ther. 7, 275 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1675_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10020-020-00174-2","volume":"26","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. The SP1-12LOX axis promotes chemoresistance and metastasis of ovarian cancer. Mol. Med. 26, 39 (2020).","journal-title":"Mol. Med."},{"key":"1675_CR25","doi-asserted-by":"publisher","first-page":"15349","DOI":"10.1016\/S0021-9258(18)55398-9","volume":"265","author":"DJ Prockop","year":"1990","unstructured":"Prockop, D. J. Mutations that alter the primary structure of type I collagen. The perils of a system for generating large structures by the principle of nucleated growth. J. Biol. Chem. 265, 15349\u201315352 (1990).","journal-title":"J. Biol. Chem."},{"key":"1675_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ijc.28399","volume":"134","author":"PN Yu","year":"2014","unstructured":"Yu, P. N. et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int. J. Cancer 134, 542\u2013551 (2014).","journal-title":"Int. J. Cancer"},{"key":"1675_CR27","first-page":"5037","volume":"17","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z., Wang, Y., Zhang, J., Zhong, J. & Yang, R. COL1A1 promotes metastasis in colorectal cancer by regulating the WNT\/PCP pathway. Mol. Med. Rep. 17, 5037\u20135042 (2018).","journal-title":"Mol. Med. Rep."},{"key":"1675_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-020-00140-5","volume":"5","author":"Y Wu","year":"2021","unstructured":"Wu, Y. et al. Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers. npj Precis. Oncol. 5, 3 (2021).","journal-title":"npj Precis. Oncol."},{"key":"1675_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13105-019-00703-6","volume":"75","author":"C Zhang","year":"2019","unstructured":"Zhang, C. et al. Caveolin-1 promotes Rfng expression via Erk\u2013Jnk\u2013p38 signaling pathway in mouse hepatocarcinoma cells. J. Physiol. Biochem. 75, 549\u2013559 (2019).","journal-title":"J. Physiol. Biochem."},{"key":"1675_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00288-4","volume":"7","author":"H Hu","year":"2017","unstructured":"Hu, H. et al. Elevated COX-2 expression promotes angiogenesis through EGFR\/p38-MAPK\/Sp1-dependent signalling in pancreatic cancer. Sci. Rep. 7, 470 (2017).","journal-title":"Sci. Rep."},{"key":"1675_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188435","volume":"1874","author":"B Wen","year":"2020","unstructured":"Wen, B., Xu, L. Y. & Li, E. M. LOXL2 in cancer: regulation, downstream effectors and novel roles. Biochim. Biophys. Acta Rev. Cancer 1874, 188435 (2020).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1675_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1634\/theoncologist.2017-0024","volume":"22","author":"AB Benson","year":"2017","unstructured":"Benson, A. B. et al. A phase II randomized, double-blind, placebo-controlled study of simtuzumab or placebo in combination with gemcitabine for the first-line treatment of pancreatic adenocarcinoma. Oncologist 22, 241\u2013e215 (2017).","journal-title":"Oncologist"},{"key":"1675_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1634\/theoncologist.2016-0479","volume":"22","author":"JR Hecht","year":"2017","unstructured":"Hecht, J. R. et al. A phase II, randomized, double-blind, placebo-controlled study of simtuzumab in combination with FOLFIRI for the second-line treatment of metastatic KRAS mutant colorectal adenocarcinoma. Oncologist 22, 243\u2013e223 (2017).","journal-title":"Oncologist"},{"key":"1675_CR34","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/antiox10020312","volume":"10","author":"S Ferreira","year":"2021","unstructured":"Ferreira, S., Saraiva, N., Rijo, P. & Fernandes, A. S. LOXL2 inhibitors and breast cancer progression. Antioxidants 10, 312 (2021).","journal-title":"Antioxidants"},{"key":"1675_CR35","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00109-023-02369-6","volume":"101","author":"YS Lee","year":"2023","unstructured":"Lee, Y. S. et al. The role of LOXL2 induced by glucose metabolism-activated NF-\u03baB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC. J. Mol. Med. 101, 1449\u20131464 (2023).","journal-title":"J. Mol. Med."},{"key":"1675_CR36","doi-asserted-by":"publisher","first-page":"30000","DOI":"10.1074\/jbc.C113.502310","volume":"288","author":"HJ Moon","year":"2013","unstructured":"Moon, H. J. et al. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. J. Biol. Chem. 288, 30000\u201330008 (2013).","journal-title":"J. Biol. Chem."},{"key":"1675_CR37","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1038\/sj.emboj.7600781","volume":"24","author":"H Peinado","year":"2005","unstructured":"Peinado, H. et al. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J. 24, 3446\u20133458 (2005).","journal-title":"EMBO J."},{"key":"1675_CR38","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1158\/1541-7786.MCR-14-0233","volume":"12","author":"H Hase","year":"2014","unstructured":"Hase, H. et al. LOXL2 status correlates with tumor stage and regulates integrin levels to promote tumor progression in ccRCC. Mol. Cancer Res. 12, 1807\u20131817 (2014).","journal-title":"Mol. Cancer Res."},{"key":"1675_CR39","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.cellsig.2014.05.010","volume":"26","author":"BR Kim","year":"2014","unstructured":"Kim, B. R. et al. Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1. Cell Signal. 26, 1765\u20131773 (2014).","journal-title":"Cell Signal."},{"key":"1675_CR40","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/bjc.1996.53","volume":"73","author":"JM Bartlett","year":"1996","unstructured":"Bartlett, J. M. et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer 73, 301\u2013306 (1996).","journal-title":"Br. J. Cancer"},{"key":"1675_CR41","first-page":"613","volume":"17","author":"J Fischer-Colbrie","year":"1997","unstructured":"Fischer-Colbrie, J. et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. 17, 613\u2013619 (1997).","journal-title":"Anticancer Res."},{"key":"1675_CR42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.pccm.2024.08.002","volume":"2","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Overcoming EGFR-TKI resistance by targeting the tumor microenvironment. Chin. Med. J. Pulm. Crit. Care Med. 2, 151\u2013161 (2024).","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"1675_CR43","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","volume":"21","author":"J Mendelsohn","year":"2003","unstructured":"Mendelsohn, J. & Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787\u20132799 (2003).","journal-title":"J. Clin. Oncol."},{"key":"1675_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/CAD.0b013e32832afc24","volume":"20","author":"MN Bijman","year":"2009","unstructured":"Bijman, M. N., van Berkel, M. P., Kok, M., Janmaat, M. L. & Boven, E. Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines. Anticancer Drugs 20, 450\u2013460 (2009).","journal-title":"Anticancer Drugs"},{"key":"1675_CR45","doi-asserted-by":"publisher","first-page":"12000","DOI":"10.3390\/ijms130912000","volume":"13","author":"N Gottschalk","year":"2012","unstructured":"Gottschalk, N., Kimmig, R., Lang, S., Singh, M. & Brandau, S. Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity. Int. J. Mol. Sci. 13, 12000\u201312016 (2012).","journal-title":"Int. J. Mol. Sci."},{"key":"1675_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.drup.2011.02.004","volume":"14","author":"M Murphy","year":"2011","unstructured":"Murphy, M. & Stordal, B. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist. Updat. 14, 177\u2013190 (2011).","journal-title":"Drug Resist. Updat."},{"key":"1675_CR47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ygyno.2008.04.018","volume":"110","author":"J Konner","year":"2008","unstructured":"Konner, J. et al. A phase II study of cetuximab\/paclitaxel\/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol. Oncol. 110, 140\u2013145 (2008).","journal-title":"Gynecol. Oncol."},{"key":"1675_CR48","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.canep.2012.06.005","volume":"36","author":"T Gui","year":"2012","unstructured":"Gui, T. & Shen, K. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol. 36, 490\u2013496 (2012).","journal-title":"Cancer Epidemiol."},{"key":"1675_CR49","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.3390\/biomedicines10092113","volume":"10","author":"A Rendell","year":"2022","unstructured":"Rendell, A. et al. Targeting tyrosine kinases in ovarian cancer: small molecule inhibitor and monoclonal antibody, where are we now? Biomedicines 10, 2113 (2022).","journal-title":"Biomedicines"},{"key":"1675_CR50","first-page":"1820","volume":"115","author":"D Al-U\u2019datt","year":"2019","unstructured":"Al-U\u2019datt, D., Allen, B. G. & Nattel, S. Role of the lysyl oxidase enzyme family in cardiac function and disease. Cardiovasc. Res. 115, 1820\u20131837 (2019).","journal-title":"Cardiovasc. Res."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01675-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01675-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01675-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:02:13Z","timestamp":1775214133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01675-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1675"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01675-6","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The collection of specimens was approved by the ethical committee of the Women\u2019s Hospital, Zhejiang University School of Medicine, and informed consent was obtained. Animal experiments were approved by Animal Ethical and Welfare Committee of Zhejiang Chinese Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}